Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. Salbutamol activates β2‑adrenergic receptors, raising cyclic AMP levels and causing smooth‑muscle relaxation. Together they produce additive bronchodilation, quickly opening narrowed airways.

The dose of Ipramol Steri‑Neb is determined by the prescribing clinician based on the patient’s age, severity of disease, and response to therapy. Healthcare professionals select the appropriate volume and frequency for nebulization according to established treatment guidelines.

Safety data for Ipramol Steri‑Neb in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ipramol Steri‑Neb combines an anticholinergic (ipratropium) with a short‑acting β2‑agonist (salbutamol), offering dual mechanisms that can be more effective than single‑agent bronchodilators in certain patients. Compared with monotherapy, the combination may provide faster and more sustained relief of bronchospasm, especially in moderate to severe COPD or acute asthma attacks.

Store Ipramol Steri‑Neb at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from moisture, direct sunlight and extreme temperatures to maintain product stability.

Ipramol Steri‑Neb is a nebulizer solution intended for inhalation. The prescribed volume is placed in a compatible nebulizer device, which converts the liquid into an aerosol that the patient inhales through a mouthpiece or mask, following the clinician’s instructions for duration and frequency.

Serious risks include paradoxical bronchospasm, angioedema, significant tachycardia or arrhythmias, severe allergic reactions, and hyperglycemia. Patients should be monitored for these events, and treatment should be discontinued immediately if any serious reaction occurs.

Ipramol Steri‑Neb should be avoided in individuals with a known hypersensitivity to ipratropium, salbutamol, or any formulation excipients. Caution is also advised for patients with narrow‑angle glaucoma, severe cardiac arrhythmias, or uncontrolled hyperthyroidism, and it should be used only under medical supervision.